{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:24:19Z","timestamp":1787963059938,"version":"build-2784847793"},"reference-count":141,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Glioblastoma (GBM) remains largely resistant to immunotherapy despite the success of immune checkpoint inhibitors in other solid tumors. Phase III trials have not demonstrated survival benefit for anti-PD-1 monotherapy, likely reflecting the GBM tumor microenvironment\u2019s profound myeloid-driven immunosuppression, low neoantigen burden, intratumoral heterogeneity, and adaptive resistance. These challenges have driven the development of next-generation immunotherapy biologics designed to reprogram the tumor microenvironment and overcome the innate and adaptive resistance of GBM. This review synthesizes advances in immunotherapy biologics including immune checkpoint combinations, cytokine and immunomodulatory proteins, adoptive cell therapies, vaccines, and oncolytic viruses, highlighting key preclinical insights and emerging clinical trial results. We conclude that improved tumor subtyping and immune profiling will be crucial to guide combination strategies that may achieve durable clinical benefit in GBM.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1775093","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:56:48Z","timestamp":1773817008000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Next-generation immunotherapy biologics for glioblastoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Ethan","family":"Schonfeld","sequence":"first","affiliation":[{"name":"Stanford University School of Medicine, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sjoholm","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Ha","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Liu","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Nageeb","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas","family":"Annagiri","sequence":"additional","affiliation":[{"name":"Stanford School of Humanities and Sciences, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Stanford University School of Medicine, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Stanford University School of Medicine, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Stanford University School of Medicine, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic therapy for melanoma: ASCO guideline update","volume":"41","author":"Seth","year":"2023","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent glioblastoma: results from CheckMate 143","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2415557122","article-title":"Radiation-induced cellular plasticity primes glioblastoma for forskolin-mediated differentiation","volume":"122","author":"He","year":"2025","journal-title":"Proc Natl Acad Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.1038\/s41467-023-41694-9","article-title":"Breaking barriers for glioblastoma with a path to enhanced drug delivery","volume":"14","author":"Noorani","year":"2023","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10456-019-09691-z","article-title":"Vessel co-option in glioblastoma: emerging insights and opportunities","volume":"23","author":"Seano","year":"2020","journal-title":"Angiogenesis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuron.2025.12.012","article-title":"Reactive oligodendrocytes promote glioblastoma progression through CCL5\/CCR5-mediated glioma stem cell maintenance","volume":"114","author":"Mikolajewicz","year":"2026","journal-title":"Neuron"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00985-4","article-title":"Glioblastoma shift from bulk to infiltrative growth is guided by plexin-B2-mediated microglia alignment in invasive niches","volume":"6","author":"Kang","year":"2025","journal-title":"Nat Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163446","article-title":"Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy","volume":"133","author":"Khan","year":"2023","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000988","article-title":"T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies","volume":"34","author":"Jansen","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of immunotherapy resistance: lessons from glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00124.2024","article-title":"Hypoxia conduces the glioma progression by inducing M2 macrophage polarization via elevating TNFSF9 level in a histone-lactylation-dependent manner","volume":"327","author":"Li","year":"2024","journal-title":"Am J Physiol Cell Physiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573039","article-title":"Lactate-mediated metabolic reprogramming of tumor-associated macrophages: implications for tumor progression and therapeutic potential","volume":"16","author":"Jin","year":"2025","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm5214","article-title":"Distinct myeloid-derived suppressor cell populations in human glioblastoma","volume":"387","author":"Jackson","year":"2025","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41467-024-46193-z","article-title":"Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression","volume":"15","author":"Khan","year":"2024","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08633-8","article-title":"Programs, origins and immunomodulatory functions of myeloid cells in glioma","volume":"640","author":"Miller","year":"2025","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41467-022-28372-y","article-title":"Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target","volume":"13","author":"Abdelfattah","year":"2022","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01402","article-title":"Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma","volume":"11","author":"DeCordova","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.696402","article-title":"Targeting immunometabolism in glioblastoma","volume":"11","author":"Mohan","year":"2021","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/neuonc\/now287","article-title":"Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1\/PD-L1 mechanism in glioblastoma","volume":"19","author":"Antonios","year":"2017","journal-title":"Neuro Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-3878","article-title":"Galectin-9 mediates the functions of microglia in the hypoxic brain tumor microenvironment","volume":"84","author":"Lee","year":"2024","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0489","article-title":"Immune checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell\u2013mediated inflammation and immunosuppression","volume":"7","author":"Xu","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0020","article-title":"TLR2 promotes glioma immune evasion by downregulating MHC class II molecules in microglia","volume":"6","author":"Qian","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/s41467-020-15129-8","article-title":"Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity","volume":"11","author":"von Roemeling","year":"2020","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964898","article-title":"Tumor-associated microglia and macrophages in glioblastoma: from basic insights to therapeutic opportunities","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41525-023-00381-w","article-title":"CNS tumor stroma transcriptomics identify perivascular fibroblasts as predictors of immunotherapy resistance in glioblastoma patients","volume":"8","author":"Zarodniuk","year":"2023","journal-title":"NPJ Genom Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.ccell.2024.08.012","article-title":"Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence","volume":"42","author":"Watson","year":"2024","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41419-021-04359-3","article-title":"CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41467-023-37361-8","article-title":"Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae174","article-title":"The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: a systematic review","volume":"6","author":"Schonfeld","year":"2024","journal-title":"Neuro Oncol Adv"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1535","article-title":"Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf033","article-title":"Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomas","volume":"7","author":"Sahebjam","year":"2025","journal-title":"Neuro Oncol Adv"},{"key":"B40","doi-asserted-by":"publisher","first-page":"370ra180","DOI":"10.1126\/scitranslmed.aag2942","article-title":"Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM","volume":"8","author":"Mathios","year":"2016","journal-title":"Sci Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac025","article-title":"Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: results from exploratory phase I cohorts of CheckMate 143","volume":"4","author":"Omuro","year":"2022","journal-title":"Neuro-Oncol Adv"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0489","article-title":"Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression","volume":"7","author":"Xu","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1158\/2159-8290.CD-22-0455","article-title":"Targeting microglial metabolic rewiring synergizes with immune-checkpoint blockade therapy for glioblastoma","volume":"13","author":"Ye","year":"2023","journal-title":"Cancer Discov"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85841","article-title":"Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype","volume":"1","author":"Gabrusiewicz","year":"2016","journal-title":"JCI Insight"},{"key":"B45","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41467-022-28523-1","article-title":"T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10","volume":"13","author":"Ravi","year":"2022","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2402","article-title":"Glioblastoma-derived IL-6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth","volume":"25","author":"Lamano","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000949","article-title":"IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma","volume":"8","author":"Weber","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104254","article-title":"IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy","volume":"359","author":"Weber","year":"2021","journal-title":"Cell Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01223","article-title":"IL-6 and IL-8 are linked with myeloid-derived suppressor cell accumulation and correlate with poor clinical outcomes in melanoma patients","volume":"9","author":"Tobin","year":"2019","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1038\/s41467-021-23832-3","article-title":"Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn5649","article-title":"Immunotoxin-\u03b1CD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models","volume":"15","author":"Parker","year":"2023","journal-title":"Sci Transl Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw7843","article-title":"Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance","volume":"12","author":"Akkari","year":"2020","journal-title":"Sci Transl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101944","article-title":"Antisense oligonucleotides for rapid translation of gene therapy in glioblastoma","volume":"16","author":"Desgraves","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1563-y","article-title":"Electrical and synaptic integration of glioma into neural circuits","volume":"573","author":"Venkatesh","year":"2019","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1564-x","article-title":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","volume":"573","author":"Venkataramani","year":"2019","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41586-023-06036-1","article-title":"Glioblastoma remodelling of human neural circuits decreases survival","volume":"617","author":"Krishna","year":"2023","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06678-1","article-title":"Glioma synapses recruit mechanisms of adaptive plasticity","volume":"623","author":"Taylor","year":"2023","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nature24014","article-title":"Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma","volume":"549","author":"Venkatesh","year":"2017","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009486","article-title":"EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses","volume":"12","author":"Lertsumitkul","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.981583","article-title":"Neuropilin-1 modulates the 3D invasive properties of glioblastoma stem-like cells","volume":"10","author":"Kerherv\u00e9","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143739","article-title":"The use of targeted cytokines as cancer therapeutics in glioblastoma","volume":"15","author":"Sooreshjani","year":"2023","journal-title":"Cancers"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0947","article-title":"Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8 T cells and enhances survival in mouse glioma models","volume":"28","author":"Campian","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4333.bloodjournal87104333","article-title":"Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR)","volume":"87","author":"Puri","year":"1996","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa196","article-title":"Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas","volume":"23","author":"Rossmeisl","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb2311","article-title":"Immunocytokines are a promising immunotherapeutic approach against glioblastoma","volume":"12","author":"Weiss","year":"2020","journal-title":"Sci Transl Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf2281","article-title":"Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell\u2013dependent regression of glioblastoma","volume":"15","author":"Look","year":"2023","journal-title":"Sci Transl Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2617","article-title":"Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes","volume":"24","author":"Mohme","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/science.adr3026","article-title":"Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity","volume":"388","author":"Chiu","year":"2025","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo4778","article-title":"Bifunctional cancer cell\u2013based vaccine concomitantly drives direct tumor killing and antitumor immunity","volume":"15","author":"Chen","year":"2023","journal-title":"Sci Transl Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4384","article-title":"Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma","volume":"28","author":"Meister","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl4106","article-title":"Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models","volume":"14","author":"Birocchi","year":"2022","journal-title":"Sci Transl Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3835","article-title":"Antitumor immunity mediated by engineered stem cells exploiting TRAIL-induced cell death and FLT3L immunomodulation","volume":"31","author":"Van Schaik","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae149","article-title":"Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma","volume":"26","author":"Montoya","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00448-0","article-title":"Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity","volume":"3","author":"Tian","year":"2022","journal-title":"Nat Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"TPS2581","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS2581","article-title":"Phase II study of pembrolizumab plus SurVaxM for glioblastoma at first recurrence","volume":"38","author":"Ahluwalia","year":"2020","journal-title":"JCO"},{"key":"B77","unstructured":"Peereboom\n              D\n            \n          \n          Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence\n          \n          2024"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.706186","article-title":"Sargramostim (rhu GM-CSF) as cancer therapy (systematic review) and an immunomodulator. A drug before its time","volume":"12","author":"Lazarus","year":"2021","journal-title":"Front Immunol"},{"key":"B79","unstructured":"Khasraw\n              M\n            \n          \n          Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma (I-ATTAC)\n          \n          2024"},{"key":"B80","unstructured":"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme\n          \n          2025"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-199606000-00006","article-title":"Long-term treatment of Malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: An open pilot study","volume":"38","author":"Salazar","year":"1996","journal-title":"Neurosurgery"},{"key":"B82","unstructured":"CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII\n          \n          2019"},{"key":"B83","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/ITT.S61590","article-title":"Update on use of aldesleukin for treatment of high-risk metastatic melanoma","volume":"4","author":"Amaria","year":"2015","journal-title":"ITT"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor\u2013transduced T cells targeting EGFRvIII in patients with glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J Immunother"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac285","article-title":"Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial","volume":"25","author":"Sampson","year":"2023","journal-title":"Neuro-Oncology"},{"key":"B86","unstructured":"Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma\n          \n          2022"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08997-x","article-title":"Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity","volume":"643","author":"Faust Akl","year":"2025","journal-title":"Nature"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R200003200","article-title":"Cytokine and cytokine receptor pleiotropy and redundancy","volume":"277","author":"Ozaki","year":"2002","journal-title":"J Biol Chem"},{"key":"B89","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.coi.2016.03.006","article-title":"Immunocytokines for cancer treatment: past, present and future","volume":"40","author":"Neri","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41419-025-07771-1","article-title":"EGFRvIII-positive glioblastoma contributes to immune escape and Malignant progression via the c-Fos-MDK-LRP1 axis","volume":"16","author":"Yuan","year":"2025","journal-title":"Cell Death Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J Immunother"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-007-9424-1","article-title":"Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma","volume":"85","author":"Mineo","year":"2007","journal-title":"J Neuro-Oncol"},{"key":"B94","article-title":"IL13RA2 is overexpressed in Malignant gliomas and related to clinical outcome of patients","volume":"12","author":"Zeng","year":"2020","journal-title":"Am J Transl Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac185","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2023","journal-title":"Neuro-Oncol Adv"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae064.372","article-title":"IMMU-01. Pioneering quad-targeting CAR T cell therapy in pediatric CNS tumors \u2013 analysis from the initial patients treated on the first-in-human phase 1 trial BRAINCHILD-04","volume":"26","author":"Ronsley","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011382","article-title":"Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma","volume":"13","author":"De Sostoa","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","article-title":"Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD","volume":"42","author":"Shanley","year":"2024","journal-title":"Cancer Cell"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf201.0480","article-title":"CTIM-23. First-in-human immunotherapy targeting lymphopenia in recurrent glioblastoma multiform (GBM): NAI and PD-L1 T-HANK plus bevacizumab with complete response","volume":"27","author":"Khagi","year":"2025","journal-title":"Neuro-Oncology"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46343-3","article-title":"synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy","volume":"15","author":"Lupo","year":"2024","journal-title":"Nat Commun"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101931","article-title":"CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines","volume":"6","author":"Look","year":"2025","journal-title":"CR Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.09.026","article-title":"Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety","volume":"33","author":"Li","year":"2025","journal-title":"Mol Ther"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1273986","article-title":"\u03b3\u03b4 T cells as a potential therapeutic agent for glioblastoma","volume":"14","author":"Kang","year":"2023","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041249","article-title":"CAR-T therapy in GBM: Current challenges and avenues for improvement","volume":"15","author":"Pant","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-02977-8","article-title":"CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma","volume":"132","author":"Strassheimer","year":"2025","journal-title":"Br J Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"9718","DOI":"10.1038\/s41467-024-54129-w","article-title":"Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRP\u03b3-derived CD47 blocker","volume":"15","author":"Martins","year":"2024","journal-title":"Nat Commun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107507118","article-title":"Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells","volume":"118","author":"Wang","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0777","article-title":"Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion","volume":"26","author":"Luo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/btm2.10097","article-title":"TGF-\u03b2-responsive CAR-T cells promote anti-tumor immune function","volume":"3","author":"Hou","year":"2018","journal-title":"Bioeng Transl Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040761","article-title":"Tumor heterogeneity in glioblastomas: From light microscopy to molecular pathology","volume":"13","author":"Becker","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adt1211","article-title":"A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastoma","volume":"18","author":"Xie","year":"2026","journal-title":"Sci Transl Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2024.11.010","article-title":"Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy","volume":"32","author":"Logun","year":"2025","journal-title":"Cell Stem Cell"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou348","article-title":"A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: The ACT III study","volume":"17","author":"Schuster","year":"2015","journal-title":"Neuro Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1140","article-title":"Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): Results of a double-blind randomized phase II trial","volume":"26","author":"Reardon","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.04.003","article-title":"RNA aggregates harness the danger response for potent cancer immunotherapy","volume":"187","author":"Mendez-Gomez","year":"2024","journal-title":"Cell"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2025.101975","article-title":"Oncolytic virus-mediated immunomodulation in glioblastoma: Insights from clinical trials and challenges","volume":"79","author":"Piranlioglu","year":"2025","journal-title":"Semin Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1307935110","article-title":"Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model","volume":"110","author":"Cheema","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"B131","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: A phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: Replication and immunotherapeutic effects in recurrent Malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"B135","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: A phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adv2881","article-title":"Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses","volume":"17","author":"Ling","year":"2025","journal-title":"Sci Transl Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102400","article-title":"Targeting CSF1R alone or in combination with PD1 in experimental glioma","volume":"13","author":"Przystal","year":"2021","journal-title":"Cancers"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1200\/jco.2014.32.15_suppl.2023","article-title":"A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma","volume":"32","author":"Butowski","year":"2014","journal-title":"J Clin Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02167-5","article-title":"The multilayered transcriptional architecture of glioblastoma ecosystems","volume":"57","author":"Nomura","year":"2025","journal-title":"Nat Genet"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npae028","article-title":"Biomarkers of immunotherapy in glioblastoma","volume":"11","author":"Savage","year":"2024","journal-title":"Neuro-Oncol Pract"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1775093\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:56:55Z","timestamp":1773817015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1775093\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":141,"alternative-id":["10.3389\/fimmu.2026.1775093"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1775093","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1775093"}}